Claims for Patent: 5,932,611

Summary for Patent: 5,932,611

Title:	Angiogenesis inhibitor for the treatment of cancer
Abstract:	The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
Inventor(s):	Wuthier; Roy E. (Columbia, SC), Nie; Daotai (Detroit, MI)
Assignee:	University of South Carolina (Columbia, SC)
Application Number:	08/975,813
Patent Claims:	1. A method for treating cancer sensitive to the compounds below in a patient, comprising administering to said patient a therapeutically active dosage of a composition comprising 5-amino-2,2-dimethyl-6-[3'-(R,S) amino-4'-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one, wherein said composition is administered via a pharmaceutically or veterinarily acceptable carrier, for a time effective to treat said cancer by inhibiting the formation of new blood vessels in said patient. 2. A method according to claim 1, wherein said therapeutically active dosage is in the range of about 0.2 .mu.g to about 200 g. 3. A method according to claim 1, wherein said composition is administered via a mucosal route. 4. A method according to claim 1, wherein said composition is administered via a parenteral route. 5. A method according to claim 1, wherein said cancer is a solid tumor sensitive to said compounds. 6. A method according to claim 1, wherein said pharmaceutically or veterinarily acceptable carrier is chosen from the group consisting of saline, glucose, sterile water and mixtures thereof. 7. A method for inhibiting metastasis sensitive to the compounds below in a patient comprising administering to said patient a therapeutically active dosage of a composition comprising 5-amino-2,2-dimethyl-6-[3'-(R,S) amino4'-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one, wherein said composition is administered via a pharmaceutically or veterinarily acceptable carrier, for a time effective to inhibit said metastasis by inhibiting the formation of new blood vessels. 8. A method according to claim 7, wherein said therapeutically active dosage is in the range of about 0.2 .mu.g to about 200 g. 9. A method according to claim 7, wherein said composition is administered via a mucosal route. 10. A method according to claim 7, wherein said composition is administered via a parenteral route. 11. A method according to claim 7, wherein said pharmaceutically or veterinarily acceptable carrier is chosen from the group consisting of saline, glucose, sterile water and mixtures thereof.

Details for Patent 5,932,611

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23